semaglutide for parkinson's Weight-loss drug does not slow Alzheimer's disease, two clinical trials find Brain-Targeting Drug Similar to Ozempic

Schizophr Res 172(13):101105 Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK (2016) Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies

As of July 2026, the FDA's 503B exclusion is still a proposal

This growth is predominantly fueled by a rising consumer demand for functional foods and dietary supplements aimed at weight management and energy enhancement, coupled with the robust expansion of the sports nutrition sector

This analysis further assessed whether the increase in DRP was a GLP-1 specific effect, or rather caused by a robust and early glucose lowering as suggested by several other studies, where acute and large reductions in glucose concentrations may initially and transiently worsen DRP, yet prevent or delay onset or progression of DRP in the long term (123128)

Researchers should reference the specific published literature for the research model and question being studied, as cycling patterns vary across research traditions